Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19926744 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL13957311 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL31409466 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL29067230 | 0.85 | CYP3A4 (0.64) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL7986608 | 0.84 | CYP3A4 (0.61) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL2601402 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2CYP3A4MEN1KMT2AHSD17B10 | |
| SCHEMBL8736580 | 0.84 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL30992968 | 0.81 | CYP3A4 (0.68) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL547618 | 0.81 | CYP3A4 (0.68) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL7148530 | 0.81 | CYP3A4 (0.72) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104341307-A | Phenylacetic acid derivative and anti-tumor application thereof | PHARMACEUTICAL RES & DEV CORP OF JINGPENGHUI | 2015-02-11 | — | — | CN | claimed |
| EP-4734977-A2 | NOVEL TRPV1 AGONISTS AND USES THEREOF | Neucures, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006675-A9 | NOVEL TRPV1 AGONISTS AND USES THEREOF | NEUCURES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025006675-A2 | NOVEL TRPV1 AGONISTS AND USES THEREOF | NEUCURES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4436964-A1 | ANALOGUES OF MDMA FOR MODULATING SERT, DAT, AND / OR NET ACTIVITY | The University Of Western Australia (AU) | 2024-10-02 | — | — | EP | disclosed |
| CN-114989131-B | N' - (2- (benzo [1,3] dioxolan-5-yl) acyl) aryl hydrazide compound as well as synthesis and application thereof | 云南大学 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023092195-A1 | ANALOGUES OF MDMA FOR MODULATING SERT, DAT, AND / OR NET ACTIVITY | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023092195-A1 | ANALOGUES OF MDMA FOR MODULATING SERT, DAT, AND / OR NET ACTIVITY | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2023-06-01 | — | — | WO | disclosed |
| EP-3719013-B1 | PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | WUXI BIOCITY BIOPHARMACEUTICS CO LTD (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-5965576-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| US-5891871-A | 2-AMINO-3-(3-HYDROXY-5-METHYLISOXAZ-4-YL)PROPIONIC ACID RECEPTOR ANTAGONISTS; TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA OR SURGERY; OR TREATING NEURODEGENERATIVE DISEASES. | COCENSYS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5705505-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1998-01-06 | — | — | US | disclosed |
| US-5703108-A | Bone deposition by certain prostaglandin agonists | PFIZER INC. (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1997034878-A1 | SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5589489-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1996-12-31 | — | — | US | disclosed |
| EP-0734383-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
| US-4880817-A | O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-11-14 | — | — | US | disclosed |
| US-4822800-A | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | TBXA2R, P2RY11, TPMT | SMN1; SMN2 1251/4885ALDH1A1 1298/4885CYP3A4 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.